The introduction of Retatrutide ZPHC, at a dosage of 120mg, is generating considerable interest within the medical community. This innovative dual GIP and GLP-1 receptor medication seems to offer significant improvements in fat loss compared to previous therapies. Initial patient data have demonstrated significant reductions in body fat percentage,